Combination Therapy Development for Prostate Cancer

Combination therapy for prostate cancer is an approach in which multiple therapies are used in combination to increase the effectiveness of therapy and reduce the development of drug resistance. Alfa Cytology focuses on the development of combination therapies in the field of prostate cancer and aims to provide customers with comprehensive one-stop combination therapy development services.

Introduction to Combination Therapy

Androgens are essential for normal prostate development and differentiation, but have also been implicated in the development and progression of prostate cancer. Because of the dependence of prostate cancer cells on androgens, androgen deprivation therapy (ADT), which blocks androgen receptor (AR) signaling, is the standard of care for metastatic prostate cancer, including surgical and medical approaches.

Fig. 1 Prostate cancer progression and therapy options. (Miller, D. R., et al. 2021)

However, androgen deprivation therapy usually does not cure metastatic prostate cancer, and patients may develop castration-resistant prostate cancer. Despite the availability of chemotherapy, including the use of new androgen signaling inhibitors and immunotherapy, patients continue to die from this disease. Thus, castration-resistant prostate cancer is a fatal disease. Currently, combination therapy is an important strategy for treating this deadly disease.

Advantages of Combination Therapy

• Enhance therapeutic effect

Unlike monotherapies, combination therapies can slow disease progression by targeting the complex biological pathways and cancer cell characteristics of prostate cancer and enhancing the effectiveness of therapie.

• Reduce drug resistance

Long-term monotherapy may lead to cancer cells becoming resistant to drugs. However, it is difficult for cancer cells to become resistant to multiple drugs at the same time, so combination therapies can reduce resistance.

• Prolong survival

Combination therapy has been shown to prolong progression-free survival and overall survival in numerous trials and studies.

Combination Therapy Development for Prostate Cancer

In the current era, research advances in prostate cancer combination therapies have accelerated and cover several aspects, mainly PARP inhibitor combination therapy, combination of chemotherapeutic agents, and ADT combination therapy.

Our Services

The field of combination therapy development services is rapidly expanding, driven by new technologies. Alfa Cytology can provide one-stop combination therapy development services.

Our Advantages

We are committed to providing efficient, innovative and reliable development solutions by leveraging our in-depth professional knowledge, adopting cutting-edge technologies, and enforcing strict quality control standards.

Professional Knowledge

Cutting-Edge Technologies

Quality Control

With our expertise and resources, we aim to contribute to the development of combination therapy drugs, thereby improving patient outcomes and contributing to the fight against prostate cancer. If you are interested in our services, please don't hesitate to contact us for further information and pricing details.